N-glycosylation in non-invasive and invasive intraductal papillary mucinous neoplasm.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
received:
29
12
2022
accepted:
21
07
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Intraductal papillary mucinous neoplasms (IPMNs), often found incidentally, are potentially malignant cystic tumors of the pancreas. Due to the precancerous nature, IPMNs lacking malignant features should be kept on surveillance. The follow-up relies on magnetic resonance imaging, which has a limited accuracy to define the high-risk patients. New diagnostic methods are thus needed to recognize IPMNs with malignant potential. Here, aberrantly expressed glycans constitute a promising new area of research. We compared the N-glycan profiles of non-invasive IPMN tissues (n = 10) and invasive IPMN tissues (n = 10) to those of non-neoplastic pancreatic controls (n = 5) by matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry. Both IPMN subgroups showed increased abundance of neutral composition H4N4 and decrease in H3N5F1, increase in sialylation, and decrease in sulfation, as compared to the controls. Furthermore, invasive IPMN showed an increase in terminal N-acetylhexosamine containing structure H4N5, and increase in acidic complex-type glycans, but decrease in their complex fucosylation and sulfation, as compared to the controls. In conclusion, the N-glycan profiles differed between healthy pancreatic tissue and non-invasive and invasive IPMNs. The unique glycans expressed in invasive IPMNs may offer interesting new options for diagnostics.
Identifiants
pubmed: 37580349
doi: 10.1038/s41598-023-39220-4
pii: 10.1038/s41598-023-39220-4
pmc: PMC10425445
doi:
Substances chimiques
Polysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13191Informations de copyright
© 2023. Springer Nature Limited.
Références
Tanaka, M. et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12, 183–197 (2012).
doi: 10.1016/j.pan.2012.04.004
pubmed: 22687371
Holmberg, M. et al. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma – A Swedish nationwide register-based study. Pancreatology 23, 90–97 (2023).
doi: 10.1016/j.pan.2022.12.003
pubmed: 36522260
Del Chiaro, M. et al. European experts consensus statement on cystic tumours of the pancreas. Dig. Liver Dis. 45, 703–711 (2013).
doi: 10.1016/j.dld.2013.01.010
pubmed: 23415799
Distler, M. et al. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann. Surg. 258, 324–330 (2013).
doi: 10.1097/SLA.0b013e318287ab73
pubmed: 23532107
Intraductal Papillary Mucinous Neoplasm of the Pancreas. (2014).
Bassi, C. et al. Management of complications after pancreaticoduodenectomy in a high volume centre: Results on 150 consecutive patients. Dig. Surg. 18(6), 453–458 (2001).
doi: 10.1159/000050193
pubmed: 11799295
Fong, Z. V. & Fernández-del Castillo, C. Intraductal Papillary Mucinous Neoplasm of the Pancreas. Surg. Clin. N. Am. 96, 1431–1445 (2016).
doi: 10.1016/j.suc.2016.07.009
pubmed: 27865286
Rong, Y. et al. Prognostic value of histological subtype in intraductal papillary mucinous neoplasm of the pancreas. Medicine 96, (2017).
Pinho, S. S. & Reis, C. A. Glycosylation in cancer: Mechanisms and clinical implications. Nat. Rev. Cancer 15, 540–555 (2015).
doi: 10.1038/nrc3982
pubmed: 26289314
Mereiter, S., Balmaña, M., Campos, D., Gomes, J. & Reis, C. A. Glycosylation in the era of cancer-targeted therapy: Where are we heading?. Cancer Cell 36, 6–16 (2019).
doi: 10.1016/j.ccell.2019.06.006
pubmed: 31287993
Mereiter, S., Balmaña, M., Gomes, J., Magalhães, A. & Reis, C. A. Glycomic approaches for the discovery of targets in gastrointestinal cancer. Front. Oncol. 6, 1–19 (2016).
doi: 10.3389/fonc.2016.00055
Kalthoff, H., Kreiker, C., Schmiegel, W. H., Greten, H. & Thiele, H. G. Characterization of CA 19–9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 46, 3605–3607 (1986).
pubmed: 3708591
McDowell, C. T. et al. Imaging mass spectrometry and lectin analysis of n-linked glycans in carbohydrate antigen-defined pancreatic cancer tissues. Mol. Cell. Proteomics 20, (2021).
Munkley, J. The glycosylation landscape of pancreatic cancer (review). Oncol. Lett. 17, 2569–2575. https://doi.org/10.3892/ol.2019.9885 (2019).
doi: 10.3892/ol.2019.9885
pubmed: 30854032
pmcid: 6388511
Akimoto, Y. et al. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 15, 432–438 (2015).
doi: 10.1016/j.pan.2015.05.470
pubmed: 26052067
Zhong, A. et al. Diagnostic significance of serum IgG galactosylation in CA19-9-negative pancreatic carcinoma patients. Front. Oncol. 9, 114 (2019).
doi: 10.3389/fonc.2019.00114
pubmed: 30873386
pmcid: 6402387
Sarrats, A. et al. Glycocylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin. Appl. 4(4), 432–448 (2010).
doi: 10.1002/prca.200900150
pubmed: 21137062
Kaprio, T. et al. N-glycomic profiling as a tool to separate rectal adenomas from carcinomas. Mol. Cell. Proteomics 14, 277–288 (2015).
doi: 10.1074/mcp.M114.041632
pubmed: 25452313
Saarinen, L. et al. Glycomic profiling highlights increased fucosylation in pseudomyxoma peritonei. Mol. Cell. Proteomics 17, 2107–2118 (2018).
doi: 10.1074/mcp.RA118.000615
pubmed: 30072579
pmcid: 6210226
Satomaa, T. et al. The N-glycome of human embryonic stem cells. BMC Cell Biol. 10, 1–18 (2009).
doi: 10.1186/1471-2121-10-42
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Source. J. R. Stat. Soc. Ser. B (Methodol.) 57(1), 289–300 (1995).
Balog, C. I. A. et al. N-glycosylation of colorectal cancer tissues: A liquid chromatography and mass spectrometry-based investigation. Mol. Cell. Proteomics 11, 571–585 (2012).
doi: 10.1074/mcp.M111.011601
pubmed: 22573871
pmcid: 3434767
Leijon, H. et al. N-Glycomic profiling of pheochromocytomas and paragangliomas separates metastatic and nonmetastatic disease. J. Clin. Endocrinol. Metab. 102, 3990–4000 (2017).
doi: 10.1210/jc.2017-00401
pubmed: 28938401
pmcid: 6283447
Lumibao, J. C., Tremblay, J. R., Hsu, J. & Engle, D. D. Altered glycosylation in pancreatic cancer and beyond. J. Exp. Med. https://doi.org/10.1084/jem.20211505 (2022).
doi: 10.1084/jem.20211505
pubmed: 35522218
pmcid: 9086500
Satomaa, T. et al. Analysis of the human cancer glycome identifies a novel group of tumor-associated N-acetylglucosamine glycan antigens. Cancer Res. 69, 5811–5819 (2009).
doi: 10.1158/0008-5472.CAN-08-0289
pubmed: 19584298
Mann, B. F., Goetz, J. A., House, M. G., Schmidt, C. M. & Novotny, M. V. Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol. Cell. Proteomics 11, 1–11 (2012).
doi: 10.1074/mcp.M111.015792
An, H. J., Kronewitter, S. R., de Leoz, M. L. A. & Lebrilla, C. B. Glycomics and disease markers. Curr. Opin. Chem. Biol. 13, 601–607 (2009).
doi: 10.1016/j.cbpa.2009.08.015
pubmed: 19775929
pmcid: 2788081
Elder, E. E. et al. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod. Pathol. 16, 246–255 (2003).
doi: 10.1097/01.MP.0000056982.07160.E3
pubmed: 12640105
Thomas, A., Teicher, B. A. & Hassan, R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 17, e254–e262 (2016).
doi: 10.1016/S1470-2045(16)30030-4
pubmed: 27299281
pmcid: 6601617
Prendergast, J. M. et al. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs 9, 615–627 (2017).
doi: 10.1080/19420862.2017.1290752
pubmed: 28281872
pmcid: 5419082
Yang, M. C. et al. Preclinical studies of OBI-999: A novel globo h-targeting antibody-drug conjugate. Mol. Cancer Ther. 20, 1121–1132 (2021).
doi: 10.1158/1535-7163.MCT-20-0763
pubmed: 33722855
Basturk, O. et al. The 2019 WHO classification of tumours of the digestive system. (2019).
Nummela, P. et al. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei. Glycobiology 31, 211–222 (2021).
doi: 10.1093/glycob/cwaa079
pubmed: 33539510
Amato, E. et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J. Pathol. 233, 217–227 (2014).
doi: 10.1002/path.4344
pubmed: 24604757
pmcid: 4057302
Nummela, P. et al. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int. J. Cancer 136, E282–E289 (2015).
doi: 10.1002/ijc.29245
pubmed: 25274248